

Punitamig Biosimilar - Research Grade

Product Code: ICH6021

More Information

Species Reactivity: Human

Target: VEGFA + PD-L1

Concentration: 5mg/ml

Isotype: Human IgG1(L234A/L235A)-kappa-VH

product name H2: Punitamig Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P15692;Q9NZQ7

Shipping Conditions: Blue ice

background: Combining anti-angiogenic and immune-checkpoint blockade, dual targeting of VEGFA and PD-L1 is an actively studied strategy to reshape the tumour microenvironment. This research-grade bispecific antibody is an unconjugated, non-therapeutic analog of punitamig, designed to engage both VEGFA and PD-L1 for preclinical research into combined angiogenesis and checkpoint modulation. It is validated for functional assays and provided for research use only (RUO). Produced to rigorous in vivo standards as an ultra-pure, low-endotoxin preparation and available in scalable milligram (mg) to gram (g) quantities, it equips high-throughput and heavy-usage laboratories for in vitro screening, in vivo tumour-immunology models and dual-mechanism characterization.

Purification Method: This monoclonal antibody was purified using IEC

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE



Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.